What is Excellergy?
Excellergy is a biotechnology firm dedicated to developing a pioneering portfolio of trifunctional effector cell response inhibitors (ECRIs). These inhibitors are designed to combat severe allergic diseases, aiming to substantially improve the quality of life for affected patients. The company's focus on novel therapeutic approaches positions it at the forefront of innovation in allergy treatment.
How much funding has Excellergy raised?
Excellergy has raised a total of $70M across 1 funding round:
Series A
$70M
Series A (2025): $70M with participation from Decheng Capital, Samsara BioCapital, and Red Tree Venture Capital
Key Investors in Excellergy
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies. With over $2.1 billion in capital, the firm aims to build legendary companies by leveraging revolutionary technologies and strong market presence.
Samsara BioCapital
Samsara BioCapital is focused on investing to create transformative therapeutics for patients. The company partners with scientists, physicians, drug developers, and business leaders to support the next generation of therapeutic breakthroughs. With over 500 years of combined experience, they aim to drive innovation in the biopharmaceutical sector.
Red Tree Venture Capital
Red Tree Venture Capital is a San Francisco Bay Area venture capital firm focused on creating and investing in transformative life sciences companies that discover, develop and commercialize highly innovative therapeutics and medical technologies.
What's next for Excellergy?
The substantial enterprise-level funding, particularly the recent major strategic investment, indicates Excellergy is poised for significant scaling and advancement of its ECRI technology. This capital infusion will likely accelerate clinical development, expand research capabilities, and potentially facilitate market entry for its first-in-class treatments. The company's trajectory suggests a move towards broader clinical application and strategic partnerships within the pharmaceutical and biotechnology landscape.
See full Excellergy company page
